Pharmacokinetics of Petrelintide in Participants with Impaired Hepatic Function

This study evaluates the pharmacokinetics of petrelintide in subjects with hepatic impairment. The primary objective is to assess how impaired liver function affects the absorption, distribution, metabolism, and excretion of the study drug. This evaluation is clinically relevant to determine if hepatic dysfunction necessitates dose adjustments to maintain therapeutic efficacy and avoid toxicity. The study scope is defined by the following classifications: 6: Pharmacokinetic.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers and individuals with hepatic impairment. The cohort includes both male and female subjects. The age range of the participants is categorized under codes 3 and 4. The primary objective is to assess pharmacokinetic parameters.

This Phase 3 clinical trial is designed to evaluate the pharmacokinetics of petrelintide in individuals with impaired hepatic function. The study methodology involves a comparative assessment of pharmacokinetic parameters between participants with hepatic impairment and healthy volunteers. The research sequence commences with a screening visit to determine eligibility based on specific medical criteria. Following successful screening, participants will undergo subsequent study visits to monitor the administration and metabolic profile of the study drug. The trial includes follow-up assessments and concludes with an end-of-study visit. The total duration of participant involvement is determined by the individual study schedule. Early termination from the study may occur if predefined safety or protocol-related conditions are met.

The clinical trial is designed to evaluate pharmacokinetic parameters in healthy or hepatic impaired volunteers. Assessment focuses on the characterization of drug disposition through specific analytical methodologies to determine the profile of the study product.